In the treatment of cancer with direct targeting antibodies, the suppressive effect of FcγRIIb is a well-documented problem (Clynes et al., 2000) and several therapeutic strategies to overcome it have been suggested (Roghanian et al., 2018). This evidence concerns the gene FCGR2B and cancer.